FDA approves patch to treat depression in adults

02/28/2006 | MSNBC

The FDA has approved Emsam, a selegiline transdermal patch to treat depression in adults, but the drug will have to carry a black-box warning for suicide. The patch is a product of Bristol-Myers Squibb and Somerset Pharmaceuticals, which is a joint venture between Mylan Laboratories and Watson Pharmaceuticals.

View Full Article in:

MSNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY